Based at Takeda's Cambridge research campus, Christopher Arendt is a member of Takeda's Research Senior Leadership Team responsible for Immunology and Oncology research through to early clinical proof-of-concept. Working with a global network of outstanding biotech and academic collaborators, his teams in Cambridge, San Diego and Japan are seeking to translate innovative scientific discoveries into modality-diverse medicines that address the needs of specific patient populations.
Prior to joining Takeda in 2015, Christopher Arendt spend more than 13 years at Sanofi, where he led teams advancing novel immunotherapies for cancers and inflammatory diseases to the clinic. He obtained his PhD in Immunology from the University of Alberta and carried out his postdoctoral training with Dan Littman at the Skirball Institute of Biomolecular Medicine at NYU Medical Center, supported by the Medical Research Council of Canada and Howard Hughes Medical Institute.